Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy.
Br J Cancer
; 117(7): 921-924, 2017 Sep 26.
Article
em En
| MEDLINE
| ID: mdl-28797029
ABSTRACT
BACKGROUND:
Immune-mediated myocarditis is an uncommon adverse effect of immune checkpoint inhibition and is associated with a high rate of mortality.METHODS:
In this reported case, a 64-year-old woman with right temporo-parietal glioblastoma IDH-WT was treated with nivolumab, temozolomide and radiation therapy on a clinical trial. She developed malignant arrhythmias secondary to histologically confirmed severe immune-mediated myocarditis. She was treated with equine anti-thymocyte globulin (ATGAM) due to development of malignant arrhythmias refractory to high-dose corticosteroids.RESULTS:
This report describes the only case of immune-mediated myocarditis treated with ATGAM resulting in a favourable outcome.CONCLUSIONS:
Use of ATGAM should be considered in cases of steroid-refractory immune-mediated myocarditis and administered in close consultation with a cardiac transplant team experienced in the use of this agent.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Encefálicas
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Glioblastoma
/
Miocardite
/
Soro Antilinfocitário
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article